Follow The Filings

CRL Charles River Labs International Inc.

Health Care, filed as CHARLES RIV LABS INTL INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Sold by 2 managers in 2026 Q2

  • 4 Owners
  • Max 3.4%
  • $854M
  • 1 reduce 1 exit 2 small

In 2026 Q2 Murray Stahl trimmed Charles River Labs International, and Lee Ainslie sold out.

Who owns this now

Largest portfolio weights among holders, up to 3.4% (John Rogers, Ariel Investments). Not free-float ownership.

  1. John Rogers Add 3.4%
  2. Bill Nygren / Oakmark Add 0.67%
  3. David Witzke 0.36%
  4. Murray Stahl Reduce 0.02%

Who owns CRL

Sorted by value, long equity only, as of 2026 Q2.

History
Bill Nygren / Oakmark, Harris Associates L P 0.67%, was 0.49% Small add +4.1% 2,241,144 $508M History
John Rogers, Ariel Investments 3.4%, was 2.8% Small add +4.3% 1,506,185 $342M History
David Witzke, Avidity Partners Management 0.36% Hold 10,000 $2.3M History
Murray Stahl, Horizon Kinetics Asset Management 0.02% Reduce −41.7% 7,103 $1.6M History
Lee Ainslie, Maverick Capital exited 2026 Q2 Last 2026 Q1 0.02% Exit −0.02% 8,178 $1.4M History

4 current, 1 exited last period, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by CRL's executives, directors and 10% owners in the last 12 months, from their Form 4s

All CRL insider trades
  • $7,338 bought by 2 insiders
  • $3M sold by 3 insiders outside a trading plan
  • $49.1M sold by 3 insiders under 10b5-1 plans
  1. James C Foster Director
    Planned sale
    $8.4M 24,042 shares at $350.00 43% of stake
    Traded Oct 22 Filed Oct 26
    ↗
  2. Shannon M Parisotto CEVP, Disc & Safety Assessment
    Planned sale
    $743K 2,156 shares at $344.41 31% of stake
    Traded Oct 21 Filed Oct 23
    ↗
  3. Shannon M Parisotto CEVP, Disc & Safety Assessment
    Planned sale
    $303K 981 shares at $308.44 17% of stake
    Traded Oct 5 Filed Oct 7
    ↗
  4. Glenn Coleman CFO
    Buy
    $2,974 10 shares at $297.43 +<0.1% to stake
    Traded Sep 30 Filed Oct 2
    ↗
  5. James C Foster Director
    Planned sale
    $10.1M 33,561 shares at $300.00 52% of stake
    Traded Aug 25 Filed Aug 27
    ↗
  6. Shannon M Parisotto CEVP, Disc & Safety Assessment
    Planned sale
    $600K 2,039 shares at $294.12 30% of stake
    Traded Aug 19 Filed Aug 20
    ↗
  7. Nancy C Andrews Director
    Sale
    $163K 573 shares at $285.24 29% of stake
    Traded Aug 18 Filed Aug 20
    ↗
  8. Birgit Girshick CEO
    Planned sale
    $1.8M 6,500 shares at $279.90 15% of stake
    Traded Aug 11 Filed Aug 13
    ↗
  9. Shannon M Parisotto CEVP, Disc & Safety Assessment
    Planned sale
    $1M 3,714 shares at $279.66 44% of stake
    Traded Aug 11 Filed Aug 13
    ↗
  10. James C Foster Director
    Planned sale
    $7.9M 28,733 shares at $275.00 48% of stake
    Traded Aug 10 Filed Aug 11
    ↗
  11. Michael Gunnar Knell SVP, Finance and CAO
    Sale
    $1.7M 6,645 shares at $260.38 36% of stake
    Traded Aug 6 Filed Aug 10
    ↗
  12. Victoria L Creamer EVP & Chief People Officer
    Sale
    $1.1M 4,179 shares at $259.16 12% of stake
    Traded Aug 6 Filed Aug 10
    ↗
  13. Shannon M Parisotto CEVP, Disc & Safety Assessment
    Planned sale
    $1.3M 5,046 shares at $263.00 51% of stake
    Traded Aug 5 Filed Aug 6
    ↗
  14. James C Foster Director
    Planned sale
    $16.9M 75,000 shares at $225.00 70% of stake
    Traded Jun 29 Filed Jul 1
    ↗
  15. Joseph W LaPlume EVP, Corp Strategy & Develop
    Buy
    $4,364 25 shares at $174.54 +0.1% to stake
    Traded Mar 3 Filed Mar 4
    ↗

Also filed in the last 12 months, not counted as buying or selling: 33 stock grants, 32 share withholdings for taxes, 17 gifts, and 14 option exercises.

Congress

3 members of Congress traded CRL in the last three years: 3 buys and 2 sales. 1 member listed it in 2025 annual reports.

All Congress trades
  1. Jefferson Shreve R-IN-6 Sell $15K–$50K May 12, 2025 filed Jun 22, 2025
  2. Jefferson Shreve R-IN-6 Buy $15K–$50K May 8, 2025 filed Jun 22, 2025
  3. Robert P. Bresnahan, Jr. R-PA-8 Sell $1K–$15K May 15, 2025 filed May 31, 2025
  4. Robert P. Bresnahan, Jr. R-PA-8 Buy $15K–$50K Apr 8, 2025 filed May 8, 2025
  5. Julie Johnson D-TX-32Joint Buy $1K–$15K Jan 15, 2025 filed Feb 12, 2025

SEC filings

Recent issuer filings from EDGAR, 6 shown.

Filed Form Detail Links
8-K 7.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $4.13B $4.05B $4.02B
Net income $474.62M $22.2M -$144.34M
Net margin * 11.5% 0.5% -3.6%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $1.61B $1.4B $1.45B
Total non-current assets * $6.59B $6.13B $5.69B
Total assets $8.2B $7.53B $7.14B
Total current liabilities $1.06B $0.994B $1.12B
Total non-current liabilities * $3.48B $3.03B $2.8B
Total equity $3.6B $3.46B $3.16B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $683.9M $734.58M $737.65M
Cash from investing -$563.16M -$245.09M -$209.32M
Cash from financing -$85.52M -$550.93M -$536.73M
Net change in cash $43.27M -$78.91M $10.43M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.